CocrystalPharmaInc.jpg
Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
05 janv. 2021 08h00 HE | Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
CocrystalPharmaInc.jpg
Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
24 févr. 2020 08h00 HE | Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used to...
CocrystalPharmaInc.jpg
Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
11 févr. 2020 08h35 HE | Cocrystal Pharma, Inc.
– Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage...
CocrystalPharmaInc.jpg
COCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING
31 oct. 2019 09h00 HE | Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
CocrystalPharmaInc.jpg
COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
30 oct. 2019 16h45 HE | Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
CocrystalPharmaInc.jpg
Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
22 janv. 2019 08h00 HE | Cocrystal Pharma, Inc.
- Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as a part of combination...
CocrystalPharmaInc.jpg
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
20 sept. 2018 08h00 HE | Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
09 août 2018 08h00 HE | Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
CocrystalPharmaInc.jpg
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
28 juin 2018 07h35 HE | Cocrystal Pharma, Inc.
- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal”...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Inclusion in Russell Microcap® Index
25 juin 2018 08h00 HE | Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...